Hologic, Inc. (NASDAQ:HOLX) Shares Sold by Amundi

Amundi reduced its position in Hologic, Inc. (NASDAQ:HOLX - Free Report) by 3.7% during the 4th quarter, according to its most recent filing with the SEC. The firm owned 1,508,099 shares of the medical equipment provider's stock after selling 57,873 shares during the quarter. Amundi owned about 0.67% of Hologic worth $109,699,000 as of its most recent filing with the SEC.

A number of other large investors also recently bought and sold shares of HOLX. General Partner Inc. purchased a new position in Hologic during the fourth quarter worth about $26,000. Groupama Asset Managment raised its stake in shares of Hologic by 9.9% during the 3rd quarter. Groupama Asset Managment now owns 33,177 shares of the medical equipment provider's stock worth $27,000 after buying an additional 2,999 shares in the last quarter. Venturi Wealth Management LLC raised its stake in shares of Hologic by 156.3% during the 4th quarter. Venturi Wealth Management LLC now owns 428 shares of the medical equipment provider's stock worth $31,000 after buying an additional 261 shares in the last quarter. First Horizon Advisors Inc. lifted its holdings in shares of Hologic by 38.3% in the 3rd quarter. First Horizon Advisors Inc. now owns 484 shares of the medical equipment provider's stock valued at $39,000 after buying an additional 134 shares during the period. Finally, Smartleaf Asset Management LLC boosted its stake in shares of Hologic by 36.9% in the fourth quarter. Smartleaf Asset Management LLC now owns 590 shares of the medical equipment provider's stock valued at $43,000 after buying an additional 159 shares in the last quarter. Hedge funds and other institutional investors own 94.73% of the company's stock.

Hologic Trading Down 0.7 %

Shares of NASDAQ HOLX traded down $0.40 during midday trading on Thursday, reaching $60.70. 2,339,023 shares of the stock were exchanged, compared to its average volume of 2,366,874. The company has a current ratio of 3.49, a quick ratio of 2.78 and a debt-to-equity ratio of 0.52. The company has a market capitalization of $13.62 billion, a P/E ratio of 19.15, a P/E/G ratio of 2.14 and a beta of 0.97. The stock has a 50 day moving average price of $67.65 and a 200-day moving average price of $74.94. Hologic, Inc. has a 52-week low of $60.33 and a 52-week high of $84.67.

Remove Ads

Hologic (NASDAQ:HOLX - Get Free Report) last issued its quarterly earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share for the quarter, beating the consensus estimate of $1.02 by $0.01. Hologic had a return on equity of 19.72% and a net margin of 18.42%. Equities research analysts expect that Hologic, Inc. will post 4.28 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

HOLX has been the subject of a number of recent analyst reports. Jefferies Financial Group started coverage on Hologic in a report on Tuesday, December 10th. They issued a "hold" rating and a $85.00 target price for the company. Morgan Stanley reduced their price objective on shares of Hologic from $84.00 to $82.00 and set an "equal weight" rating for the company in a research note on Monday, January 13th. Stephens restated an "overweight" rating and issued a $84.00 price target on shares of Hologic in a report on Thursday, February 6th. Evercore ISI dropped their price objective on Hologic from $76.00 to $73.00 and set an "in-line" rating for the company in a research note on Thursday, February 6th. Finally, Wolfe Research began coverage on Hologic in a research report on Friday, December 13th. They set a "peer perform" rating on the stock. Eleven analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, Hologic has a consensus rating of "Hold" and a consensus price target of $84.62.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.